Astellas Pipeline Set For Patent Cliff Rebound
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Astellas struggled in 2010 due to generic competition on its blockbusters Prograf (tacrolimus) and Flomax (tamsulosin), but the company's late-stage pipeline looks to put the company in a good position to rebound from its 2010 patent cliff
You may also be interested in...
AstraZeneca Strengthens Diabetes R&D With Option On Astellas/Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
Astellas Considers Options To Shed All Or Parts Of Diabetes Unit Prosidion
TOKYO - Astellas is weighing its options for metabolic subsidiary Prosidion, likely divesting all or part of it, as the company continues its integration, and shedding, of OSI Pharmaceuticals. If it sells off Prosidion, Astellas will be left with few pipeline entries in the diabetes space